How we remember the COVID-19 pandemic will be decided by the journalists of today who are editing and documenting these unusual times.
In the case of COVID-19, clinical trials – like many other planned activities – have been impacted and many companies have been forced to make some tough choices. When making the difficult, yet necessary, decision to delay a trial, communicating clearly and strategically across all affected audiences is critically important.
Many companies are facing challenging decisions on whether to proceed with clinical trials in the coming months as countries experience varying degrees of lockdown.
Medical congresses – crucial for the presentation of trial data, scientific exchange and the opportunity to engage with medical professionals, patient advocates, media and analysts – have been cancelled, postponed or are moving to virtual/part virtual.